Nasdaq
$5.94▲ 1.37%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $578.2MShares out 97.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 10.8After-hours26.10.09 08:124Ownership#●●●
Anteris Technologies Global Corp.
L1 Capital Pty Ltd, a major shareholder of Anteris Technologies Global Corp., reported changes in its beneficial ownership of securities as of October 6, 2026. This filing is a Form 4 statement regarding insider ownership activity.…more
$5.94+1.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6Pre-market26.10.06 19:184Ownership
Anteris Technologies Global Corp.
Insider L1 Capital Pty Ltd reported their beneficial ownership of Anteris Technologies Global Corp. securities as of October 2, 2026. This filing is a standard Form 4 disclosure regarding changes in insider holdings.…more
$5.94+1.37%vs prev closeView filingShare - 10.2Overnight26.10.02 09:094Ownership
Anteris Technologies Global Corp.
L1 Capital Pty Ltd has filed a Form 4 to report changes in beneficial ownership of securities in Anteris Technologies Global Corp. This filing serves as a standard disclosure regarding shifts in equity holdings by a major shareholder or insider.…more
$5.94+1.37%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoOvernight26.10.20 14:15#●●●#●●●
Anteris Secures German Regulatory Clearance for DurAVR Trial Expansion
Anteris has received regulatory approval in Germany to expand its PARADIGM clinical trial comparing DurAVR THV with commercial TAVRs. This expansion into Europe's largest TAVR market is expected to strengthen clinical data and competitive positioning.…more
$5.94+1.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoOvernight26.10.20 10:12
●●●●●●●● ●●●●● ●●●●●●
Anteris has received regulatory clearance in Germany to expand its global pivotal trial for the DurAVR transcatheter heart valve. This move allows the company to accelerate patient recruitment in Europe's largest market, though clinical outcomes remain the key factor for future progress.…more
$5.94+1.37%vs prev close - 9.24Overnight26.09.24 16:59
●●●●●●●● ●●●●● ●●●●●●
Anteris Technologies' subsidiary has amended its supply and quality agreement with Harvey Industries, extending the term until December 31, 2026. The announcement confirms a continuation of the existing partnership without disclosing specific financial terms.…more
$5.94+1.37%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report